1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. KALA BIO Acquires Combangio

M&A Deal Summary

KALA BIO Acquires Combangio

On November 15, 2021, KALA BIO acquired life science company Combangio for 16M USD

Acquisition Highlights
  • This is KALA BIO’s 1st transaction in the Life Science sector.
  • This is KALA BIO’s largest (disclosed) transaction.
  • This is KALA BIO’s 1st transaction in the United States.
  • This is KALA BIO’s 1st transaction in California.

M&A Deal Summary
Date 2021-11-15
Target Combangio
Sector Life Science
Buyer(s) KALA BIO
Deal Type Add-on Acquisition
Deal Value 16M USD

Target

Combangio

Menlo Park, California, United States
Combangio is a clinical-stage biotechnology company focused on developing regenerative biotherapeutics based on mesenchymal stem cell (“MSC”) secretomes. Combangio’s lead product candidate, CMB-012 (which has been renamed KPI-012), for the treatment of persistent corneal epithelial defect (“PCED”), received orphan drug designation from the U.S. Food and Drug Administration (FDA). Combangio was founded in 2014 and is based in Menlo Park, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

KALA BIO

Arlington, Massachusetts, United States
Category Company
Founded 2009
Sector Life Science
Employees38
Revenue 4M USD (2022)
DESCRIPTION

KALA BIO is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. KALA BIO was founded in 2009 and is based in Arlington, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-23 Kala Pharmaceuticals - EYSUVIS & INVELTYS

Watertown, Massachusetts, United States

Kala Pharmaceuticals' EYSUVIS & INVELTYS provides loteprednol etabonate suspension) 0.25% pharmaceutical eye drops and loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.

Sell $60M
Mergr

Solution for

Product

Company

Legal